Timothy Coughlin, Director at Travere Therapeutics, Inc. (TVTX), sold 10,000 shares at $50.07 ($501K) on 2026-06-12, disclosed to the SEC on 2026-06-16.
Scheduled sale ($501k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| LIFE | BUY | 2024-06-03 | $88K | — | Filing → |
| FATE | SELL | 2022-06-06 | $33K | — | Filing → |